GHRP-6
Preclinical ResearchAlso known as: Growth Hormone Releasing Peptide-6, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2
Educational Content Only
This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. The FDA has not evaluated many of the peptides discussed here. Always consult a licensed healthcare provider before making any health decisions.
GHRP-6 is a synthetic hexapeptide growth hormone secretagogue studied for its potent stimulation of GH release through ghrelin receptor agonism. It is one of the earliest synthesized GHRPs and has been used as a research tool to study GH secretagogue receptor pharmacology. Research also examines its notable appetite-stimulating properties through ghrelin pathway activation.
The following areas have been examined in research contexts. This does not constitute medical advice or imply proven efficacy in humans.
- Muscle Recovery & Repair
- Growth Hormone Regulation
GHRP-6 activates the ghrelin receptor (GHSR-1a) in the hypothalamus and pituitary, stimulating GH secretion. Its strong orexigenic (appetite-stimulating) effect is mediated through ghrelin pathway modulation, which is more pronounced than seen with GHRP-2 or Ipamorelin.
Primarily used as a research tool. Significant appetite stimulation reported. May elevate cortisol, prolactin, and ACTH. Not FDA-approved.
Selected peer-reviewed papers from research literature. These are educational references only and do not imply proven efficacy or safety in humans.
- Structure-activity relationships of a synthetic hexapeptide that specifically releases GH in vitro and in vivo
Bowers CY et al. (1990). Endocrinology.
Want to learn more?
Ask Research Chat about GHRP-6Half-Life
~15-60 minutes
Administration
subcutaneous injection
Legal Status (US)
Research chemical in the US. Not FDA-approved.
107 indexed research passages
Related Peptides
GHRP-2 (pralmorelin) is a synthetic hexapeptide and potent growth hormone secretagogue studied for its ability to stimulate pulsatile GH release through the ghrelin receptor. It has been investigated in clinical studies and is sometimes used diagnostically for growth hormone deficiency assessment in some countries.
Hexarelin is a synthetic hexapeptide and potent growth hormone secretagogue studied for its ability to stimulate GH release and its potential cardioprotective effects in animal models and early human studies.
IGF-1 (insulin-like growth factor 1) is an endogenous polypeptide hormone critical for growth, development, and metabolic homeostasis. It is produced primarily in the liver in response to GH signaling and acts through IGF-1 receptors on virtually all tissues. Recombinant IGF-1 (mecasermin) is FDA-approved for children with severe primary IGF-1 deficiency.
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) consisting of the full 44-amino acid GHRH sequence with a trans-3-hexenoic acid modification to improve stability. It is FDA-approved for reduction of excess abdominal fat (lipodystrophy) in HIV-infected patients receiving antiretroviral therapy, and has been studied for cognitive function in aging.